Key Highlights

  • Skye Bioscience, Inc. (NASDAQ:SKYE) indicated USD 0.7999 pre-market on Tuesday, November 10, 2026, up 15.93% from a calculated prior close of USD 0.69, a gain of about USD 0.11 per share.
  • An October 26, 2026 snapshot showed a prior close of USD 1.54, a 52-week range of USD 1.50 to USD 13.28 and 4.43 million shares, so the stock now trades below that range.
  • The Phase 2a CBeyond combination arm showed additional weight loss of 2.95 points, at 13.2% versus 10.25% for semaglutide alone, with p equal to 0.0372.
  • No company release or filing dated November 9 or November 10, 2026 was identified, so the move is not tied to a confirmed catalyst.

What Moved Skye Bioscience Pre-Market (15.93%)

Skye Bioscience quoted at USD 0.7999 pre-market on Tuesday, November 10, 2026, which is 15.93% above a calculated prior close of USD 0.69 from Monday, November 9. That prior close is about 55% below the USD 1.54 level in the October 26 snapshot, calculated, and the current quote sits 46.6% below the USD 1.50 52-week low, also calculated. The same snapshot listed 4.43 million shares and a market cap of USD 6.95 million, down 84.3% over twelve months. At USD 0.7999 and the same share count, simple arithmetic gives about USD 3.5 million, but the share count may have changed since that snapshot and is unverified.

The Rationale Behind the Move

No catalyst was identified in published coverage for November 9 or November 10, 2026. The company's investor page showed its latest items as an August 14, 2026 transaction agreement with Redx Pharma with USD 125 million in financings, and a May 20, 2026 decision to open Cohort 2 after favorable early safety data. The company has said current Capital funds operations into 2027. The October 2025 CBeyond monotherapy arm missed its primary weight-loss endpoint, while the semaglutide combination reached p of 0.0372 and a 26-week extension targets 52 weeks of data. As general context, clinical-stage biotechs often swing on trial updates, financing news, listing notices, reverse splits or sector moves in obesity drugs, and sub-USD 1 prices can attract momentum trading.

Valuation, Liquidity and Risk

At a Market Value of only a few million dollars, the company's cash may exceed its Equity value, but no current cash balance was verified, so no ratio is given. A published snapshot showed an average analyst target of USD 68.00 from four analysts, an outlier given the price, so it is not relied on here. The October 26 snapshot Volume was 18,794 shares. A share price below USD 1.00 can trigger a Nasdaq minimum bid deficiency notice after 30 consecutive Business days, a general rule. Pre-market volume is thin, spreads can be wide, dilution risk is high for nano-cap biotechs, and the quote can reverse at the 9:30 a.m. ET open. Nothing here implies the move will continue.

Where Things Stand

Skye Bioscience, Inc. (NASDAQ:SKYE) is rising 15.93% pre-market to USD 0.7999 on Tuesday, November 10, 2026, with no confirmed catalyst. The stock trades far below its USD 13.28 52-week high and below its USD 1.50 low, so the move is a rebound from a very depressed base. Trial progress, financing terms and any exchange notice are the items to watch, and the open at 9:30 a.m. ET will test the quote.